Author:
Rossi Giordano Novak,Reis José Augusto Silva,Hallak Jaime Eduardo Cecilio,Santos Rafael Guimarães dos
Abstract
This article will summarize the current knowledge and scientific evidence regarding cannabidiol as a possible pharmacological tool for anxiety disorders. Although the use of this substance in medical practice is gaining momentum, gaps can still be found in the current knowledge regarding its molecular targets, drug-to-drug interactions, efficacy in different populations, adequate dosage, duration of treatment, and correct formulation. Moreover, current evidence is still preliminary, lacking robust, blinded, and placebo-controlled clinical trials in many areas of investigation. After reading this article, readers should have a thorough understanding of the current scientific evidence regarding the use of CBD as an anxiolytic drug.
[
Psychiatr Ann
. 2023;53(6):242–246.]
Subject
Psychiatry and Mental health
Reference24 articles.
1. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association. 2013.
2. Arousal, Anxiety, and Performance: A Reexamination of the Inverted-U Hypothesis
3. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
4. World Health Organization. World mental health report: transforming mental health for all. World Health Organization. Published June 16 2022. Accessed May 2 2023. https://www.who.int/publications/i/item/9789240049338
5. Epidemiology of anxiety disorders: from surveys to nosology and back